Industry
Biotechnology
Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare endocrine disorders. The company is headquartered in Austin, Texas.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 02, 2024 | 3:50 pm
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 8:40 pm
Portfolio Pulse from Benzinga Newsdesk
June 04, 2024 | 1:01 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 8:53 pm
Portfolio Pulse from Benzinga Newsdesk
May 14, 2024 | 8:17 pm
Portfolio Pulse from Benzinga Newsdesk
April 18, 2024 | 8:08 pm
Portfolio Pulse from Benzinga Newsdesk
March 20, 2024 | 4:29 pm
Portfolio Pulse from Benzinga Newsdesk
March 20, 2024 | 12:06 pm
Portfolio Pulse from Benzinga Newsdesk
March 08, 2024 | 2:04 pm
Portfolio Pulse from Benzinga Newsdesk
March 08, 2024 | 11:52 am
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.